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application of direct measurements of change in cartilage on MRI. The
design of MRI-based efﬁcacy studies includes decisions on sample size,
based on estimations of statistical power derived from prior data or
expectations concerning progression. The sample size depends on (a) the
expected rate of progression in participants treated with placebo, (b) the
minimum size of drug effect judged to be clinically relevant, or rate of
progression expected in the active treatment arm(s), (c) the variation in
progression rate that occurs between participants, and (d) the precision of
the measurement technique. Despite results from older studies in persons
with knee OA suggesting rates of change for cartilage volume loss in
the range of 5−7% per year, more recent studies including from the
OAI have produced more conservative estimates in the range of 1−3%
per year with substantive variability. To date despite major advances
in measurement methods, structure-modifying efﬁcacy has not been
convincingly demonstrated for any of the existing pharmacologic agents.
Current trials have wanted for more responsive outcome measures both
for symptoms and structure in order to identify change.
Methods: Thus conservative study designs based on large x-ray and MRI
progression series currently in the public domain require large sample
sizes. If we could conﬁdently design studies based on smaller sample
sizes and/or shorter study durations, this would reduce the resource
implications for MRI based interventional studies.
Results: An increase in the study power could be gained by selecting
participants that have features that predict rapid progression in future
studies. Several studies have suggested that baseline clinical, biomarker
and imaging features are predictive of more rapid progression of cartilage
loss in the medial compartment of the knee. These include increased
body mass index (BMI), an increased level of type II collagen C-terminal
degradation products detected in the urine, the presence of varus mal-
alignment at the tibiofemoral joint, the presence on MRI of subchondral
bone marrow lesions or meniscal abnormalities.
Conclusions: These studies that stratify risk of OA progression will be
discussed along with their implications for screening failure rates in clinical
trials.
I-7 PLACEBO RESPONSE IN OA TRIALS
M. Doherty. University of Nottingham, Nottingham, UNITED KINGDOM
Purpose: Clinical evidence of non-speciﬁc treatment effects, often termed
“placebo effect”, has been documented in a wide range of conditions.
Such non-speciﬁc beneﬁts could result from a patient’s response to
observation and assessment (Hawthorne effect), the administration of
a therapeutic treatment or ritual (placebo treatment), or the patient-
practitioner interaction. Randomised controlled trials (RCTs) to investigate
the beneﬁts of a treatment attempt to take into account such non-speciﬁc
effects by use of a placebo control. However, some investigators have
questioned whether the placebo effect exists at all, preferring to explain
improvements from baseline on placebo in terms of natural disease
remission or chance regression to the mean. Recently we undertook a
systematic review and meta-analysis of RCTs in OA to determine whether
there is evidence for placebo effects in OA and to examine potential
determinants of the size of such effects.
Methods: A systematic literature search was undertaken using Medline,
EMBASE, Scientiﬁc Citation Index, CINAHL and Cochrane Library. Ran-
domised placebo controlled trials in OA were included. The placebo effect
was estimated as the effect size (ES) – the standard mean difference
between baseline and endpoint. This was compared with the ES obtained
from untreated (observation) controls. ES for pain was the primary
outcome. Statistical pooling was undertaken as appropriate and 95%
conﬁdence interval (CI) was used for comparison. Quality of trials was
assessed and potential determinants of placebo effect were examined
using multiple regression analysis. Partial regression coefﬁcient (b) was
used to present the adjusted size of the association.
Results: We identiﬁed 198 trials with 193 placebo groups (16,364 pa-
tients) and 14 untreated control groups (1,167 patients) that met our inclu-
sion criteria. These included a range of therapies (non-pharmacological,
pharmacological and surgical treatments). The following results were
obtained:
1. Placebo was effective at relieving pain (ES=0.51, 95%CI 0.46, 0.55).
This effect was superior to untreated control (ES=0.03, 95%CI −0.13,
0.18), supporting placebo as a real entity.
2. Placebo also improved function (ES=0.49, 95%CI 0.44, 0.54) and
stiffness (ES=0.43, 95%CI 0.38, 0.49), but the highest ES was
for physician global assessment (ES=0.66, 95%CI 0.53, 0.78). No
improvements were seen for more objective measures such as quadri-
ceps strength, knee circumference or range of movement.
3. Placebo ES for pain relief was higher with treatments that had a
larger effect, perhaps reﬂecting greater expectancy of efﬁcacy from
the patient.
4. Placebo ES increased as baseline pain and sample size increased.
5. Route of delivery affected placebo ES for pain, with highest effects
seen when given by injection (higher with multiple than single injec-
tions), needling, and topical application.
6. Placebo ES for pain was highest for hand OA (0.80, 95%CI 0.65,
0.96), intermediate for knee OA (0.54, 95%CI 0.49, 0.6) and lowest
for hip OA (0.37, 95%CI 0.21, 0.53) perhaps implying that hip OA is
more severe disease and less amenable to non-speciﬁc effects.
Conclusions: Although regarded largely as a “nuisance” in RCTs, it is
apparent that non-speciﬁc effects of treatment in OA confer greater beneﬁt
in terms of symptom improvement than the effect derived from the more
speciﬁc effect of any one treatment. This has clear implications for design
of RCTs. More importantly, however, it emphasises the potential major
role for non-treatment effects in the medical care of people with OA and
should encourage us to investigate ways of optimising such beneﬁts.
I-8 OARSI-OMERACT SET OF CRITERIA IN KNEE/HIP
OSTEOARTHRITIS TO BE USED AS A HARD ENDPOINT
IN CLINICAL TRIALS EVALUATING POTENTIAL
DISEASE-MODIFYING DRUGS
L. Gossec. Cochin Hospital, Paris Descartes University, Paris, FRANCE
Purpose: Little is known about the natural course of deterioration of pain,
physical function or joint structure as a result of hip or knee osteoarthri-
tis. An international OARSI/OMERACT working group was created; the
objectives are to develop pain, physical function and structure states
that represent the progression from early to late disease for individuals
with OA of the hip and knee. These states are planned to be used as
a “hard endpoint” in potential disease-modifying drug trials, with some
states deﬁning “heoretical need for total joint replacement”.
Methods: New questionnaires were created to assess pain and functional
impairment. Structural assessments have been compared and structural
severity was deﬁned as joint space width loss on radiographs. A large
multicenter study is ongoing to assess these criteria.
Results:Work is ongoing. Current results will be presented at the OARSI
meeting.
Conclusions: The ﬁnal objective will be to combine the 3 domains (pain,
function and structure) and to create a composite index to deﬁne states
of severity and “theoretical need for total joint replacement” in hip/knee
osteoarthritis.
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J. Kopec1, C.G. Richardson1, H. Llewellyn-Thomas2, A. Klinkhoff1,
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Purpose: Therapeutic decisions in osteoarthritis (OA) often involve trade-
offs between accepting risks of side effects and gaining pain relief.
Previous studies suggested that the risk of side effects affected treat-
ment preferences but data on patients’ preferences for speciﬁc trade-offs
between pain relief and each side effect of treatment in OA are scarce.
Our objectives were (1) to determine patients’ maximum acceptable risk
increments (MARI) for different adverse effects from OA medication and
(2) to identify the predictors of these preferences.
Methods: Participants were individuals diagnosed with OA of the hip
or knee according to standard ACR criteria, age 45−74, able to under-
stand English and mentally competent. They were stratiﬁed into three
categories of disease severity – mild, moderate, and severe. MARI were
measured with a probabilistic threshold technique (TT). Risk and pain
levels in the TT scenarios were controlled for in a 2×2 randomized facto-
rial design. Clinical, sociodemographic, and psychological characteristics
(decisional conﬂict and locus of control) of the participants were assessed
using a self-administered questionnaire.
Results: 196 subjects participated in the study. For most side effects,
higher initial-risk levels in the TT tasks were associated with subjects’
reports that they would be willing to accept higher additional risks.
Depending on the initial level of risk and pain relief, mean MARI ranged
from 3% to 5% for heart attack/stroke, 5% to 8% for stomach bleed, 13%
to 21% for hypertension, 22% to 33% for ﬂuid retention, and 23% to 35%
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for dyspepsia. Age, gender, education, physical and mental health, pain,
disability, and locus of control were not associated with MARI.
Conclusions: This study quantiﬁed osteoarthritis patients’ preferences
toward trade-offs between the risk of speciﬁc side effects of treatment
and pain relief. As expected, the average additional risk that would be
acceptable to subjects varied by side effect and increased in conjunction
with the amount of potential pain relief. For all side effects, the acceptable
level of risk for a given level of pain relief varied substantially among
the subjects. Demographic, clinical, and psychological factors did not
explain the variation in trade-off preferences. The study demonstrated the
usefulness of the probabilistic threshold technique in eliciting preferences
for trade-offs between the risk of side effects and pain relief. These
observations are important for the development of practice guidelines
for physicians and patients’ decision aids that can foster individualized,
evidence-based yet preference-sensitive care for patients with OA.
I-10 INTRA-ARTICULAR THERAPIES FOR OA: TARGETS OF
INTEREST FOR INTRA-ARTICULAR THERAPY AND
STRATEGY TO PROMOTE INCREASED EFFICACY
X. Chevalier Sr. Hoˆpital Henri Mondor, Creteil, FRANCE
Purpose: No treatments capable of slowing the osteoarthritic process
have been identiﬁed so far. Intra-articular treatment is a promising new
approach that targets locally released cytokines and proinﬂammatory
mediators in the synovial ﬂuid. Furthermore, intra-articular treatment may
be the best way to access the cartilage and synovial membrane and offers
a better risk-beneﬁt ratio than systemic treatment.
Methods: Large review of the literature concerning i.a therapies was
performed excluding current intra-articular treatments which are available,
namely, glucocorticoid injection, hyaluronic acid injection, and joint lavage.
Results: Targeted treatments designed to restore the balance between
prodegradative cytokines and anabolic factors must be developed. Il-1 b
and TNFa are the most powerful cytokines in OA. Cytokine blockers
can be injected intra-articularly, either directly or via gene therapy. Intra-
articular injection of Il-1 receptor antagonist (Il-1-ra) produced promis-
ing results in animal models of OA. Il-1-ra injection is well tolerated
in humans. However, in the only randomised controlled trial, a single
Il-1-ra (50 or 150mg) injection for knee osteoarthritis had little effect,
possibly because of the short half-life of this cytokine antagonist. Intra-
articular TNFa antagonist therapy has not been evaluated in clinical
trials in humans. Downstream from Il-1b and TNFa, caspases can be
blocked by direct injection of caspase inhibitors. Synovitis is thought
to be involved in OA progression and therefore constitutes a major
target. Depletion of synovial-membrane macrophages is associated with
decreased metalloproteinase expression. Injection of an agent that blocks
bone remodelling is an original and appealing approach. In mice, intra-
articular injection of osteoprotegerin decreased the severity of OA le-
sions. Injection of anabolic factors might promote cartilage repair, thereby
slowing the osteoarthritic process. Intra-articular injection of encapsulated
bFGF microspheres holds some promise. TGFb is an extremely powerful
stimulant of cartilage repair but also induces synovial membrane ﬁbrosis
and osteophyte growth. To avoid these adverse effects, gene therapy
using both TGFb and Smad 7 has been used in experimental models of
OA. The short half-lives of growth factors and cytokine antagonists indi-
cates a need for developing new delivery strategies, such as liposomes,
microspheres, and gene therapy, all of which exhibit limitations.
Conclusions: Intra-articular therapy holds promise for the treatment of
OA, although many issues await resolution.
I-11 FUNCTIONAL TISSUE ENGINEERING OF CARTILAGE
G.A. Ateshian1, E.G. Lima1, K.W. Ng1, L. Bian1, J.L. Cook2, C.T. Hung1.
1Columbia University, New York, NY, USA, 2University of Missouri,
Columbia, MO, USA
Purpose: The purpose of cartilage functional tissue engineering is to
produce a tissue whose mechanical properties allow it to sustain the
physiological load magnitudes encountered in vivo. Based on our under-
standing of cartilage mechanics, these properties are critically dependent
on the proteoglycan and collagen content of engineered cartilage, as well
as the ultrastructural organization of the collagen matrix.
Methods: Recent in vitro tissue engineering studies of bovine
chondrocyte-seeded agarose constructs have demonstrated that it is
possible to produce native levels of proteoglycans (~6% w/w) in 4 to
8 weeks. These results are achieved by using a chemically deﬁned
chondrogenic culture medium with administration of TGF-b3 over the ﬁrst
two weeks. The resulting equilibrium compressive mechanical properties
of the constructs match the values of native cartilage. However, collagen
content levels (~4% w/w) remain below native levels (~15% w/w), and
various strategies have been explored to further increase collagen syn-
thesis. This lower collagen content is believed to be the primary reason
that compressive properties of cartilage under dynamic loading remain
below native levels.
Results: Under these conditions, animal studies have shown that tissue
constructs show a variable ability to survive physiological loading condi-
tions in vivo. Implanted small cylindrical constructs that are buttressed by
healthy host cartilage show encouraging outcomes, whereas complete
resurfacing of an articular layer with an anatomically shaped tissue
construct fares more poorly.
Conclusions: These ﬁndings emphasize the need for functional tissue
engineering that can reproduce the mechanical properties of native
cartilage prior to in vivo implantation. The most critical need at this
time is the necessity to increase collagen content to native levels, to
improve the compressive properties of tissue constructs under dynamic
loading. Some of our recent studies show that improvements in collagen
synthesis may be achieved by delaying the relatively rapid accumulation
of proteoglycans, using selective and timely enzymatic degradation.
I-12 VALUE OF AUTOLOGOUS CELL TRANPLANTATION IN THE
TREATMENT OF OSTEOARTHRITIS
A. Facchini1, B. Grigolo2, G. Lisignoli2, C. Cavallo1, G. Desando1,
G. Giavaresi2, M. Fini2, R. Giardino1. 1Istituto Ortopedico
Rizzoli/University of Bologna, Bologna, ITALY , 2Istituto Ortopedico
Rizzoli, Bologna, ITALY
Purpose: Chondrocyte transplantation (ACT) has been a widely used
clinical strategy in the repair of damaged cartilage from lesions resulting
from traumatic injuries. In the last decade good clinical results have been
obtained together with the formation of a new tissue with many hyaline
features. More recently, suitable scaffolds loaded with chondrocytes have
been used to hold the cells in the defect site, thus, permitting their prolifer-
ation, differentiation and maintenance of the chondrocyte phenotype. We
explored the ACTapproach to treat osteoarthritis (OA) lesions by using an
experimental animal model of OA into which autologous marrow-derived
mesenchymal stem cells (MSCs) were seeded onto a hyaluronan-based
scaffold (Hyaff®-11, Fidia Advanced Biopolymers, Abano Terme, PD, Italy)
that was surgically positioned on the cartilages lesions of the knee.
Methods: Rabbit knee joints were bilaterally subjected to anterior cruciate
ligament transection (ACLT) to surgically induce OA. Autologous rabbit
MSCs have been isolated from the bone marrow, expanded in vitro and
loaded on a hyaluronan polymeric scaffold (Hyaff®-11). After 8 weeks,
necessary to the development of cartilage surface damage, animals were
treated with MSCs seeded onto Hyaff®-11 scaffold in the left condyle
and unseeded Hyaff®-11 in the controlateral knee. Untreated (sham
operated) rabbits with ACTL were used as control. All the animals were
sacriﬁced at 3 and 6 months after surgery. Morphological, histological,
histomorphometric and immunohistological evaluations were performed.
Results: OA changes developed in all animals subjected to ACLT. The
predominant macroscopically observed OA changes were mild (lateral
femoral condyle) or moderate (medial femoral condyle) ulcerations. Ar-
ticular cartilages harvested after 8 weeks from ACLT and stained with
Safranin-O clearly showed a superﬁcial ﬁbrillation with microscopic cracks
and proteoglycan depletion in the cartilage matrix particularly in the
medial condyle. At 3 and 6 months the untreated cartilage presented
the progression of OA process with evident signs of matrix loss extended
to deep zones of cartilage and particular evident in the medial condyle.
The animals treated with MSCs-HA scaffolds showed a better matrix
organization, a higher presence of proteoglycan component and normal
distribution of the cells together with an increase in collagen II expression
in comparison with rabbits treated with HA scaffold alone or the untreated
groups. In the animals treated with MSCs-HA scaffolds histomorfometric
parameters showed a decrease of modiﬁed Mankin score after 3 and
6 months after the treatment.
Conclusions: The present study demonstrates that the use of MSCs
loaded on a HA scaffold can contribute to the regeneration of a new
cartilage tissue in a rabbit model of OA. It is possible to speculate that
the beneﬁcial effects of MSCs might reﬂect, in part, some trophic and
protective activities they exert on injuried cells and tissue, togheter with
their property to differentiate into chondrocytic lineage.
